1-n-Butyl-4-chlorphthalazin | 14186-31-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-n-Butyl-4-chlorphthalazin
• 英文别名: 1-butyl-4-chloro-phthalazine；1-Butyl-4-chlorophthalazine
• CAS: 14186-31-3
• 化学式: C₁₂H₁₃ClN₂
• 分子量: 220.702
• InChiKey: YMTDOCFDZZGBSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Synthesis of hydrazine derivatives of pyridazine
  申请人：Nelson J. Deanna

  公开号：US20050137397A1

  公开（公告）日：2005-06-23

  The present invention relates to both a novel method of preparing hydralazine hydrochloride and to a novel method of preparing hydrazine derivatives of compounds containing a pyridazine ring, including, for example, pyridazines, phthalazines and other compounds containing the pyridazine ring.

  本发明涉及一种新型制备盐酸肼吡嗪和制备含吡嗪环的肼衍生物的新方法，包括例如吡嗪、邻苯二氮杂吡啉和其他含有吡嗪环的化合物。
• Stable hydrazalazine pharmaceutical compositions
  申请人：Nelson J. Deanna

  公开号：US20050137198A1

  公开（公告）日：2005-06-23

  The present invention relates to stable and highly purified stable hydralazine hydrochloride compositions and stable hydralazine-containing pharmaceutical compositions. A sterile aqueous injectable pharmaceutical composition suitable for parenteral administration is described comprising a therapeutically effective dose of hydralazine hydrochloride in a pharmaceutically acceptable carrier or diluent wherein said hydralazine hydrochloride is essentially free of phthalazines, hydrazine and metal ions. In addition, a stable sterile aqueous pharmaceutical composition comprising hydralazine hydrochloride in a pharmaceutically acceptable salt or diluent is described that is colorless and has no visible particulate matter.

  本发明涉及稳定和高度纯化的稳定的盐酸肼苯肼组合物和含有肼苯肼的制药组合物。本发明描述了一种适用于肌肉注射的无菌水溶性制药组合物，其中所述的盐酸肼苯肼在药学上可接受的载体或稀释剂中具有治疗有效剂量，且所述的盐酸肼苯肼基本上不含有邻苯二甲酸酐、肼和金属离子。此外，本发明还描述了一种稳定的无菌水溶性制药组合物，其包含在药学上可接受的盐或稀释剂中的盐酸肼苯肼，无色且没有可见的颗粒物。
• US7220858B2
  申请人：——

  公开号：US7220858B2

  公开（公告）日：2007-05-22
• US7989452B2
  申请人：——

  公开号：US7989452B2

  公开（公告）日：2011-08-02